Cytek Biosciences, Inc. (CTKB)
- Previous Close
5.63 - Open
5.69 - Bid 5.74 x 200
- Ask 5.79 x 100
- Day's Range
5.59 - 5.76 - 52 Week Range
3.80 - 12.31 - Volume
260,191 - Avg. Volume
692,025 - Market Cap (intraday)
753.546M - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.09 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
cytekbio.comRecent News: CTKB
Performance Overview: CTKB
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTKB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTKB
Valuation Measures
Market Cap
753.55M
Enterprise Value
505.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.04
Price/Book (mrq)
1.92
Enterprise Value/Revenue
2.62
Enterprise Value/EBITDA
-114.63
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.29%
Return on Assets (ttm)
-3.25%
Return on Equity (ttm)
-2.97%
Revenue (ttm)
193.02M
Net Income Avi to Common (ttm)
-12.15M
Diluted EPS (ttm)
-0.09
Balance Sheet and Cash Flow
Total Cash (mrq)
262.41M
Total Debt/Equity (mrq)
3.60%
Levered Free Cash Flow (ttm)
-400k
Research Analysis: CTKB
Company Insights: CTKB
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CTKB
CTKB: What does Argus have to say about CTKB?
CYTEK BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $6.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetCTKB: Lowering target price to $6.00
CYTEK BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $6.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetCTKB: What does Argus have to say about CTKB?
CYTEK BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $7.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetCTKB: Raising target price to $7.00
CYTEK BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $7.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target